Please assess the completion status of the following clinical trial:

Trial Title: Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic proof of prostatic adenocarcinoma without evidence of regional and/or distant metastasis, clinical stage T1c or T2a with high grade disease (Gleason 8-10) on initial biopsy, clinical stage T2b-T2c with Gleason grade 7 (4+3), or clinical stage T3. No neuroendocrine differentiation or small cell features.~* Recent (\<6 weeks prior to study entry) negative bone scan and CT of the chest and abdomen.~* Appropriate surgical candidate for radical prostatectomy and a performance status of \<2 (ECOG scale).~* Adequate bone marrow function as defined as an absolute peripheral granulocyte count \>1500 and platelet count \>100,000.~* Adequate hepatic function per the following criteria:~  * Albumin ≥2.8 g/dL~ * AST and ALT ≤5 x ULN~ * Total bilirubin \<2 mg/dL~* Adequate renal function per the following criteria:~  o Serum creatinine ≤1.5 x ULN~* Normal coagulation profile (INR ≤ 1.5, aPTT ≤ 1.5 x ULN for the lab) and no history of substantial non-iatrogenic bleeding diatheses. Use of anticoagulants is limited to local use only (for control of central line patency).~* Age ≥ 18 years~* Written informed consent to participate in this study.~Exclusion Criteria:~* Prostatic adenocarcinoma with neuroendocrine differentiation or small cell features~* Surgical resection or major surgery within 4 weeks or stereotactic biopsy within 1 week of first ADT and chemotherapy treatment~* Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy, or investigational study drug.~* Unable to tolerate multiparametric MRI or is contraindicated.~* Patients not appropriate surgical candidates for radical prostatectomy based on the evaluation of coexistent medical diseases and competing causes of death.~* Patients with uncontrolled cardiac, hepatic, renal, or neurologic/psychiatric disorder.~* Severe gastrointestinal bleeding within 12 weeks of treatment with ADT and chemotherapy~* Patients who are HIV positive or have chronic hepatitis B or C infections.~* Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, unless a 2D echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months of enrollment demonstrates a left ventricular ejection fraction \>45%.~* Sensory neuropathy grade \>1.~* History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer.~* Use of herbal products that may decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4 weeks of enrollment.~* Any other condition, including concurrent medical condition, social circumstance or drug dependency, which in the opinion of the investigator could compromise patient safety and/or compliance with study requirements

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADT + chemotherapy (Type: OTHER): Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).